Sign in
4

Changes in Ownership

Aligos Therapeutics, Inc. Filed Acc 0001567619-22-002892

Options or other derivatives

  • Chief Executive Officer acquired 404,250 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I In the form
Derivatives
BLATT LAWRENCE Chief Executive Officer 2022-02-04 Grant or award · Stock Option (Right to Buy) +323,400 323,400 D
BLATT LAWRENCE Chief Executive Officer 2022-02-04 Grant or award · Stock Option (Right to Buy) +80,850 80,850 D
Loading xslF345X03/doc1.xml…